N-substituted adenosines as novel neuroprotective A1 agonists with diminished hypotensive effects

Journal of Medicinal Chemistry

Volumn 42, Issue 18, 1999, Pages 3463-3477

  Knutsen, Lars J S ^a,c   Lau, Jesper ^c   Petersen, Hans ^b,c   Thomsen, Christian ^c   Weis, Jan U ^c   Shalmi, Michael ^c   Judge, Martin E ^c   Hansen, Anker Jon ^c   Sheardown, Malcolm J ^a,c  

^a Cerebrus Limited   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5' DEOXY 2,5' DICHLORO N [4 (PHENYLTHIO) 1 PIPERIDINYL]ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; N [1 [(2 BENZOTHIAZOLYL)THIO] 2 PROPYL] 2 CHLOROADENOSINE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROPROTECTION; NONHUMAN; RAT;

ADENOSINE; ANIMALS; BLOOD PRESSURE; BRAIN; BRAIN ISCHEMIA; CARDIOVASCULAR SYSTEM; CELL LINE; GERBILLINAE; GUINEA PIGS; HYPOTENSION; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; RATS; RATS, INBRED STRAINS; RECEPTORS, PURINERGIC P1;

EID: 0033539040     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960682u     Document Type: Article

References (126)

1. Jacobson, K. A.; van Galen, P. J. M.; Williams, M. Adenosine receptors: Pharmacology, structure-activity relationships and therapeutic potential. J. Med. Chem. 1992, 35, 407-422.
2. DeNinno, M. P. Adenosine. Annu. Rep. Med. Chem. 1998, 33, 111-120.
3. Poulsen, S.-A.; Quinn, R. J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 1998, 6, 619-641.
4. Appleman, J. R.; Erion, M. D. The therapeutic potential of agents acting via purine receptors. Exp. Opin. Invest. Drugs 1998, 7, 225-243.
5. Bhagwhat, S. S.; Williams, M. Recent progress in modulators of purinergic activity. Exp. Opin. Ther. Patents 1995, 5, 547-558.
6. Williams, M. Adenosine - a selective neuromodulator in the mammalian CNS? TINS 1984, 164-168.
7. For reviews see: Daval, J.-L.; Nehlig, A.; Nicolas, F. Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci. 1991, 49, 1435-1453. Marangos, P. J. Potential therapeutic roles for adenosine in neurologic disease. In Adenosine in the Nervous System; Stone, T. W., Ed.; Academic Press Ltd.: London, 1991; pp 217-226.
8. For reviews see: Daval, J.-L.; Nehlig, A.; Nicolas, F. Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci. 1991, 49, 1435-1453. Marangos, P. J. Potential therapeutic roles for adenosine in neurologic disease. In Adenosine in the Nervous System; Stone, T. W., Ed.; Academic Press Ltd.: London, 1991; pp 217-226.
9. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
10. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
11. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
12. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
13. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
14. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
15. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
16. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann. N. Y. Acad. Sci. 1997, 825, 23-29. von Lubitz, D. K. J. E. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 1999, 365, 9-25.
17. Young, D.; Dragunow, M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 1994, 58, 245-261.
18. Knutsen, L. J. S.; Murray, T. F. Adenosine and ATP in Epilepsy. In Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997; pp 423-447.
19. Knutsen, L. J. S.; Lau, J.; Eskesen, K.; Sheardown, M. J.; Thomsen, C.; Weis, J. U.; Judge, M. E.; Klitgaard, H. Anticonvulsant actions of novel and reference adenosine agonists. In Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology; Belardinelli, L., Pelleg, A., Eds.; Kluwer: Boston, 1995; pp 479-487. See also NNC-21-0041. Annu. Drug Data Rep. 1995, 17, 981.
20. Knutsen, L. J. S.; Lau, J.; Eskesen, K.; Sheardown, M. J.; Thomsen, C.; Weis, J. U.; Judge, M. E.; Klitgaard, H. Anticonvulsant actions of novel and reference adenosine agonists. In Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology; Belardinelli, L., Pelleg, A., Eds.; Kluwer: Boston, 1995; pp 479-487. See also NNC-21-0041. Annu. Drug Data Rep. 1995, 17, 981.
21. Deckert, J.; Gleiter, C. H. Adenosine - an endogenous neuro-protective metabolite and neuromodulator. J. Neural Transm. 1994, 43 (Suppl.), 23-31.
22. Dux, E.; Fastbom, J.; Ungerstedt, U.; Rudolphi, K.; Fredholm, B. B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 1990, 516, 248-256.
23. During, M. J.; Spencer, D. D. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 1992, 32, 618-624. Sollevi, A. Cardiovascular effects of adenosine in man. Prog. Neurobiol. 1986, 27, 319-349.
24. During, M. J.; Spencer, D. D. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 1992, 32, 618-624. Sollevi, A. Cardiovascular effects of adenosine in man. Prog. Neurobiol. 1986, 27, 319-349.
25. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Harden, T. K.; Jacobson, K. A.; Williams, M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 1994, 46, 143-156.
26. 2 receptors: structure activity relationships. Med. Chem. Rev. 1992, 12, 423-471.
27. 3 receptors: pharmacological properties, species differences and receptor functions. TIPS 1994, 15, 298-306.
28. 3 adenosine receptors: design of selective Ligands and therapeutic prospects. Drugs Future 1995, 20, 689-699. Collis, M. G.; Hourani, S. M. O. Adenosine receptor subtypes. TIPS 1993, 14, 360-366.
29. 3 adenosine receptors: design of selective Ligands and therapeutic prospects. Drugs Future 1995, 20, 689-699. Collis, M. G.; Hourani, S. M. O. Adenosine receptor subtypes. TIPS 1993, 14, 360-366.
30. 1-selective adenosine agonists. J. Med. Chem. 1985, 28, 1383-1384.
31. 1 selective adenosine receptor agonists containing a 6-hydrazinopurine moiety. Bioorg. Med. Chem. Lett. 1993, 3, 2661-2666.
32. Gustafsson, L. E.; Wiklund, C. U.; Wiklund, N. O.; Stelius, L. Subclassification of neuronal adenosine receptors. In Purines in Cellular Signalling; Jacobson, K. A., Daly, J. W., Manganiello, V., Eds.; Springer-Verlag: New York, 1990; pp 200-205.
33. 1 adenosine receptor from rat brain. Mol. Pharmacol. 1991, 40, 1-7.
34. Palmer, T. M.; Stiles, G. L. The new biology of adenosine receptors. Adv. Enzymol. Relat. Areas Mol. Biol. 1994, 69, 83-120.
35. 1 adenosine receptor from guinea pig brain. Mol. Brain Res. 1994, 26, 143-155.
36. Fredholm, B. B. Adenosine receptors in the central nervous system. News Physiol. Sci. 1995, 10, 122-128.
37. Dolphin, A. C.; Prestwich, S. A. Pertussis toxin reverses adenosine inhibition of neural glutamate release. Nature 1985, 316, 148-150.
38. Simpson, R. E.; O'Regan, M. H.; Perkins, L. M.; Phillis, J. W. Excitatory transmitter release from the ischemic rat cerbral cortex: effects of adenosine receptor agonists and antagonists. J. Neurochem. 1992, 58, 1683-1690.
39. 1 receptors in rat brain synaptosomes: transductional mechanisms, effects on glutamate release, and preservation after metabolic inhibition. Drug Dev. Res. 1995, 35, 119-129.
40. Collingridge, G. L.; Lester, R. A. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 1989, 40, 143-210.
41. Benveniste, H.; Drejer, J.; Schousboe, A.; Diemer, N. H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J. Neurochem. 1984, 43, 1369-1374.
42. Simon, R. P.; Swan, J. H.; Griffiths, T.; Meldrum, B. S. Blockade of N-Methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984, 266, 850-852.
43. Bullock, R.; Zauner, A.; Woodward, J.; Young, H. F. Massive persistent increase of excitatory amino acids following human occlusive stroke. Stroke 1995, 26, 2187-2189.
44. Schubert, P.; Rudolphi, K. A.; Fredholm, B. B.; Nakamura, Y. Modulation of nerve and glial function by adenosine - role in the development of ischemic damage. Int. J. Biochem. 1994, 26, 1227-1236.
45. Cronstein, B. N. Adenosine, an endogenous antiinflammatory agent. J. Appl. Physiol. 1994, 76, 5-13.
46. Ramkumar, V.; Nie, Z.; Rybak, L. P.; Maggirwar, S. B. Adenosine, antioxidant enzymes and cytoprotection. TIPS 1995, 16, 283-285.
47. Soricelli, A.; Postiglione, A.; Cuocolo, A.; De Chiara, S.; Ruocco, A.; Brunetti, A.; Salvatore, M.; Ell, P. J. Effect of adenosine on cerebral blood flow as evaluated by single-photon emission computed tomography in normal subjects and in patients with occlusive carotid disease. Stroke 1995, 26, 1572-1576.
48. 3 selective N-alkoxypurines as novel cytokine modulators and neuroprotectants. Drug Dev. Res. 1999, 45, 214-221.
49. Feuerstein, G. Z.; Wang, X.; Barone, F. C. Inflammatory gene expression in cerebral ischemia and trauma: potential new therapeutic targets. Ann. N. Y. Acad. Sci. 1997, 825, 179-193.
50. Mullane, K. M.; Williams, M. Adenosine and cardiovascular function. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press Inc.: Clifton, NJ, 1990; pp 289-333. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 1997, 79, 2-10. Olsson, R. A. Adenosine receptors in the cardiovascular system. Drug Dev. Res. 1997, 39, 301-307. Collis, M. G. Effect of adenosine on the coronary circulation. In Adenosine and Adenosine Nucleotides as Regulators of Cellular Function; Phillis, J. W., Ed.; CRC Press: Boca Raton, FL, 1991; pp 171-180.
51. Mullane, K. M.; Williams, M. Adenosine and cardiovascular function. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press Inc.: Clifton, NJ, 1990; pp 289-333. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 1997, 79, 2-10. Olsson, R. A. Adenosine receptors in the cardiovascular system. Drug Dev. Res. 1997, 39, 301-307. Collis, M. G. Effect of adenosine on the coronary circulation. In Adenosine and Adenosine Nucleotides as Regulators of Cellular Function; Phillis, J. W., Ed.; CRC Press: Boca Raton, FL, 1991; pp 171-180.
52. Mullane, K. M.; Williams, M. Adenosine and cardiovascular function. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press Inc.: Clifton, NJ, 1990; pp 289-333. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 1997, 79, 2-10. Olsson, R. A. Adenosine receptors in the cardiovascular system. Drug Dev. Res. 1997, 39, 301-307. Collis, M. G. Effect of adenosine on the coronary circulation. In Adenosine and Adenosine Nucleotides as Regulators of Cellular Function; Phillis, J. W., Ed.; CRC Press: Boca Raton, FL, 1991; pp 171-180.
53. Mullane, K. M.; Williams, M. Adenosine and cardiovascular function. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press Inc.: Clifton, NJ, 1990; pp 289-333. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 1997, 79, 2-10. Olsson, R. A. Adenosine receptors in the cardiovascular system. Drug Dev. Res. 1997, 39, 301-307. Collis, M. G. Effect of adenosine on the coronary circulation. In Adenosine and Adenosine Nucleotides as Regulators of Cellular Function; Phillis, J. W., Ed.; CRC Press: Boca Raton, FL, 1991; pp 171-180.
54. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 1998, 39, 3-9.
55. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 1998, 39, 3-9.
56. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 1998, 39, 3-9.
57. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 1998, 39, 3-9.
58. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res. Clin. Pract. 1998, 39, 3-9.
59. Ueeda, M.; Thompson, R. D.; Padgett, W. L.; Secunda, S.; Daly, J. W.; Olsson, R. A. Cardiovascular actions of adenosines, but not adenosine receptors, differ in rat and guinea pig. Life Sci. 1991, 49, 1351-1358.
60. 2 adenosine receptor subtypes. Eur. J. Pharmacol. 1992, 214, 199-205.
61. Barraco, R. A.; Phillis, J. W. Subtypes of adenosine receptors in the brainstem mediate opposite blood pressure changes. Neuropharmacology 1991, 30, 403-407.
62. Barraco, R. A.; Aggarwal, A. K.; Phillis, J. W.; Moron, M. A.; Wu, P. H. Dissociation of the locomotor and hypotensive effects of adenosine analogues in the rat. Neurosci. Lett. 1984, 48, 139-144.
63. White, P. J.; Rosé Meyer, R. B.; Hope, W. Functional characterization of adenosine receptors in the nucleus tractus solaritus mediating hypotensive responses in the rat. Br. J. Pharmacol. 1996, 117, 305-308.
64. 3H-CV 1808) labels a novel adenosine receptor in rat brain. J. Pharmacol. Exp. Ther. 1992, 263, 552-561.
65. Born, G. V. R.; Haslam, R. J.; Goldman, M.; Lowe, R. D. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man. Nature 1965, 205, 678-680.
66. Schaumann, E.; Kutscha, W. Clinical-pharmacological studies with a new orally active adenosine derivative. Drug Res. 1972, 22, 783-790.
67. 2 receptor ligands in different chemoconvulsive models. Eur. J. Pharmacol. 1993, 224, 221-228.
68. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Olah, M. E.; Li, X.-d.; Melman, N.; Tiwari, K. N.; Secrist, J. A., III; Schneller, S.; Cristalli, G.; Stiles, G. L.; Johnson, C. R.; IJzerman, A. P. Search for new purine-and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J. Med. Chem. 1995, 38, 1174-1178.
69. Schaumann, E.; Sclierf, G.; Pfleiderer, T.; Weber, E. The effect of administering repeated doses of phenyl-isopropyl-adenosine on fat and carbohydrate metabolism in healthy, fasted human volunteers. Drug Res. 1972, 22, 593-596.
70. Irshad, F.; Dagenais, G. R.; Fedor, E. J.; Cavanaugh, J. H. Trials with an adenosine analogue as antianginal medication. Clin. Pharmacol. Ther. 1977, 22, 470-474.
71. 6-cyclohexyl-2′-O-methyladenosine in patients with left ventricular dysfunction. Circulation 1996, 94, 1212-1215.
72. Knutsen, L. J. S.; Lau, J. Purine derivatives. Novo Nordisk A/S, WO 93/23418, Nov 25, 1993.
73. Lau, J.; Knutsen, L. J. S.; Sheardown, M. J.; Hansen, A. J. Purine derivatives. Novo Nordisk A/S, WO 94/14832, July 7, 1994.
74. Lau, J.; Knutsen, L. J. S. Purine derivatives. Novo Nordisk A/S, WO 95/07921, Mar 23, 1995.
75. Robins, M. J.; Uznanski, B. Improved acetylation and deoxygenative chlorination of guanosine; nonaqueous diazotisation-dediazotisation of a 2-aminopurine nucleoside. In Nucleic Acid Chemistry; Townsend, L. B., II., Tipson, R. S., Eds.; John Wiley and Sons: New York 1986; Vol. 3, pp 144-148.
76. Mitsunobu, O. The use of diethyl azocarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
77. 6-substituted adenosines, their pharmaceutical compositions and activity in treating ischemias. U.S. 5,430,027, July 4, 1995.
78. 6-substituted adenosines, their pharmaceutical compositions and activity in treating ischemias. U.S. 5,430,027, July 4, 1995.
79. Borchardt, R. T.; Huber, J. A.; Wu, Y. S. Convenient preparation of S-adenosylhomocysteine and related compounds. J. Org. Chem. 1976, 41, 565-567. See also: Taylor, M. D.; Moos, W. M.; Hamilton, H. M.; Szotek, D. S.; Patt, W. C.; Badger, E. W.; Bristol, J. A.; Bruns, R. F.; Heffner, T. G.; Mertz, T. G. Ribose-modified adenosine analogues as adenosine receptor agonists. J. Med. Chem. 1986, 29, 346-353.
80. Borchardt, R. T.; Huber, J. A.; Wu, Y. S. Convenient preparation of S-adenosylhomocysteine and related compounds. J. Org. Chem. 1976, 41, 565-567. See also: Taylor, M. D.; Moos, W. M.; Hamilton, H. M.; Szotek, D. S.; Patt, W. C.; Badger, E. W.; Bristol, J. A.; Bruns, R. F.; Heffner, T. G.; Mertz, T. G. Ribose-modified adenosine analogues as adenosine receptor agonists. J. Med. Chem. 1986, 29, 346-353.
81. Gurden, M. F.; Coates, J.; Ellis, F.; Evans, B.; Foster, M.; Hornby, E.; Kennedy, I.; Martin, D. P.; Strong, P.; Vardey, C. J.; Wheeldon, A. Functional characterization of three adenosine receptor types. Br. J. Pharmacol. 1993, 109, 693-698. Merkel, L. A.; Hawkins, E. D.; Colussi, D. J.; Greenland, B. D.; Smits, G, J.; Perrone, M. H.; Cox, B. F. Cardiovascular and antilipolytic effects of the adenosine agonist GR 79236. Pharmacology 1995, 51, 224-236. Thompson, C. S.; Strong, P.; Mikhailidis, D. P. Triacylglycerol lowering properties of the adenosine analogue GR 79236 during 5 days of dosing large, old rats: a pilot study. Nutr. Res. 1996, 16, 1925-1932.
82. Gurden, M. F.; Coates, J.; Ellis, F.; Evans, B.; Foster, M.; Hornby, E.; Kennedy, I.; Martin, D. P.; Strong, P.; Vardey, C. J.; Wheeldon, A. Functional characterization of three adenosine receptor types. Br. J. Pharmacol. 1993, 109, 693-698. Merkel, L. A.; Hawkins, E. D.; Colussi, D. J.; Greenland, B. D.; Smits, G, J.; Perrone, M. H.; Cox, B. F. Cardiovascular and antilipolytic effects of the adenosine agonist GR 79236. Pharmacology 1995, 51, 224-236. Thompson, C. S.; Strong, P.; Mikhailidis, D. P. Triacylglycerol lowering properties of the adenosine analogue GR 79236 during 5 days of dosing large, old rats: a pilot study. Nutr. Res. 1996, 16, 1925-1932.
83. Gurden, M. F.; Coates, J.; Ellis, F.; Evans, B.; Foster, M.; Hornby, E.; Kennedy, I.; Martin, D. P.; Strong, P.; Vardey, C. J.; Wheeldon, A. Functional characterization of three adenosine receptor types. Br. J. Pharmacol. 1993, 109, 693-698. Merkel, L. A.; Hawkins, E. D.; Colussi, D. J.; Greenland, B. D.; Smits, G, J.; Perrone, M. H.; Cox, B. F. Cardiovascular and antilipolytic effects of the adenosine agonist GR 79236. Pharmacology 1995, 51, 224-236. Thompson, C. S.; Strong, P.; Mikhailidis, D. P. Triacylglycerol lowering properties of the adenosine analogue GR 79236 during 5 days of dosing large, old rats: a pilot study. Nutr. Res. 1996, 16, 1925-1932.
84. Evans, B. 2,N-6-Disubstituted adenosines and their antihypertensive methods of use. U.S. 5,032,583, July 16, 1991.
85. Gadient, F.; Milavec, M.; Muller, E. New use of organic compounds. Sandoz Ltd., European Patent Application O 490 818 A1, June 17, 1992.
86. Gadient, F.; Mangold, B. M.; Fozard, J. R.; Prashad, M.; Kapa, P. K. Adenosine derivatives. Sandoz Ltd., WO 95/30683, Nov 16, 1995.
87. 1 MF2 smooth muscle cells. Mol. Pharmacol. 1990, 38, 660-666.
88. 6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. J. Pharmacol. Exp. Ther. 1998, 287, 21-30.
89. 6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. J. Pharmacol. Exp. Ther. 1998, 287, 21-30.
90. 6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. J. Pharmacol. Exp. Ther. 1998, 287, 21-30.
91. 2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 1991, 259, 286-294.
92. Dunwiddie, T. V.; Worth, T. Sedative and anticonvulsant effects of adenosine analogues in mouse and rat. J. Pharmacol. Exp. Ther. 1982, 220, 70-76.
93. 2 agonist CGS 21680. Pharmacol. Biochem. Behav. 1993, 45, 913-919.
94. Petersen, E. N. Selective protection by adenosine receptor agonists against DMCM-induced seizures. Eur. J. Pharmacol. 1991, 195, 261-265.
95. Sheardown, M. J.; Judge, M. E.; Eskesen, K.; Thomsen, C.; Lau, J.; Knutsen, L. J. S. Neuroprotective actions of novel and reference adenosine receptor agonists. Drug Dev. Res. 1994, 31, 320 (abstract of poster presented at 5th International Symposium on Adenosine and Adenine Nucleotides, Philadelphia, PA, May 13-16, 1994).
96. Bloch, G. A.; Pulsinelli, W. A. The adenosine receptor agonist, R-phenylisopropyladenosine, attenuates ischemic neuronal damage. J. Cereb. Blood Flow Metab. 1987, 7 (Suppl. 1), S258.
97. 13P nuclear magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 1991, 11, 453-458.
98. Bielenberg, G. W. R-PIA Protects Cortical Tissue in Permanent MCA occlusion in the rat. J. Cereb. Blood Flow Metab. 1989, 9 (Suppl. 1), S645.
99. Roussel, S.; Pinard, E.; Seylaz, J. Focal cerebral ischemia in chronic hypertension: no protection by (R)-phenylisopropyladenosine. Brain Res. 1991, 545, 171-174.
100. Von Lubitz, D. K. J. E.; Lin, R. C.-S.; Melman, N.; Ji, X.-d.; Carter, M. F.; Jacobson, K. A. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 1994, 256, 161-167.
101. von Lubitz, D. K. J, E.; Dambrosia, J. M.; Kempski, O.; Redmond, D. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of the gerbil hippocampus. Stroke 1987, 19, 1133-1139. Daval, J.-L.; von Lubitz, D. K. J. E.; Deckert, J.; Redmond, D. J.; Marangos, P. Brain Res. 1989, 491, 212-226.
102. von Lubitz, D. K. J, E.; Dambrosia, J. M.; Kempski, O.; Redmond, D. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of the gerbil hippocampus. Stroke 1987, 19, 1133-1139. Daval, J.-L.; von Lubitz, D. K. J. E.; Deckert, J.; Redmond, D. J.; Marangos, P. Brain Res. 1989, 491, 212-226.
103. Evans, M. C.; Swan, J. H.; Meldrum, B. S. An adenosine analogue, 2-chloroadenosine protects against long-term development of ischaemic cell loss in the rat hippocampus. Neurosci. Lett. 1987, 83, 287-292.
104. Von Lubitz, Dag K. J. E.; Lin, Rick C.-S.; Paul, I. A.; Beenhakker, M.; Boyd, M.; Bischofberger, N.; Jacobson, K. A. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur. J. Pharmacol. 1996, 316, 171-179.
105. 1 receptor agonist. Eur. J. Pharmacol. 1996, 302, 43-48.
106. Kulinskii, V. I.; Sufianova, G. Z.; Usov, L. A.; Ekimov, E. N. Effect of the adenosine receptor agonists on the cerebral blood flow in normal conditions and in brain ischemia. Eksp. Klin. Farmakol. 1996, 59, 37-39.
107. Baudy, R. B. Patent update: central and peripheral nervous systems. Agents for the treatment of neurodegenerative diseases: Part 4. Exp. Opin. Ther. Patents 1995, 5, 299-326.
108. Knutsen, L. J. S.; Lau, J.; Thomsen, C.; Eskesen, K.; Judge, M. E.; Weis, J. U.; Klitgaard, H.; Sheardown, M. J. Promising anticonvulsant and antiischemic effects of new, selective adenosine agonists in animal models. 33rd Annu. Meeting Am. Coll. Neuropsychopharmacol. 1994, 49 (abstract of lecture presented at ACNP Meeting, Puerto Rico, December 1994).
109. Sheardown, M. J.; Hansen, A. J.; Thomsen, C.; Judge, M. E.; Knutsen, L. J. S. Novel adenosine agonists: a strategy for stroke therapy. In Ischemic Stroke: Recent Advances in Understanding and Therapy: Grotta, J., Miller, L., Buchan, A. M., Eds.; International Business Communications, 1995; pp 187-214.
110. 2A receptor agonist CGS 21680. Drug Dev. Res. 1996, 39, 108-114.
111. 1-adenosine receptor agonist on the neurochemical, behavioral and histological consequences of ischemia. Brain Res. 1994, 641, 217-224.
112. Welsh, F. A.; Harris, V. A. Postischemic hypothermia fails to reduce ischemic injury in gerbil hippocampus. J. Cereb. Blood Flow Metab. 1991, 11, 617-620.
113. Stiles, G. L. Adenosine Receptor Subtypes: New Insights From Cloning and Functional Studies. In Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997; pp 29-37.
114. Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 1978, 43, 2923-2925.
115. Imai, K.; Nohara, A.; Honjo, M. Synthesis of purine nucleosides using iodine as catalyst. Chem. Pharm. Bull. 1966, 14, 1377-1381.
116. 3P-PhSSPh. Tetrahedron Lett. 1991, 32, 4155-4158.
117. 1 receptors. Drug Dev. Res. 1997, 42, 86-97.
118. Williams, M.; Jacobson, K. A. Radioligand Binding Assays for Adenosine Receptors. In Adenosine and Adenosine Receptors; Williams, M., Ed.; Humana Press Inc.: Clifton, NJ, 1990; pp 17-55.
119. 2 receptors in rat brain. J. Pharmacol. Exp. Ther. 1989, 251, 888-893.
120. 1 MF2 smooth muscle cells. Mol. Pharmacol. 1990, 37, 149-156.
121. 1 MF2 smooth muscle cells. Mol. Pharmacol. 1990, 37, 149-156.
122. 1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 1992, 35, 2274-2283.
123. Olsen, U. B.; Bille-Hansen, V. Exaggerated hypotension by N-formylmethionylleucylphenylalanine in indomethacin-pretreated rats. Role of toxic oxygen. Agents Actions 1985, 17, 489-494.
124. Sheardown, M. J.; Suzdak, P. D.; Nordholm, L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed for 24 h. Eur. J. Pharmacol. 1993, 236, 347-353.
125. 1-purinoceptors. Arch. Int. Pharmacodyn. Ther. 1983, 264, 180-186.
126. Bederson, J. B.; Pitts, L. H.; Tsuji, M.; Nishimura, M. C.; Davis, R. L. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17, 472-476.